Muhammad Ali, MD
Nephrology · Toccoa, GANPI 1730355850
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $48,698 of the $53,594 with a category attached, or 90.9%. 35 manufacturers reported payments, led by Lilly USA, LLC at 35.9% of the total. Among nephrology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 264 payments — averaging $203.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$19K
- Bayer$19K
- Boehringer Ingelheim$13K
- Amgen$630
- AstraZeneca$579
- Fresenius USA Marketing, Inc.$168
- plus $1K from 29 others
What the payments were for
- Speaking & faculty fees$48,69891%
- Travel & lodging$4521%
- Food & beverage$4,4448%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 31 | $19,230 |
| Bayer | 36 | $18,855 |
| Boehringer Ingelheim | 40 | $12,809 |
| Amgen(2 entities) | 41 | $630 |
| AstraZeneca(2 entities) | 33 | $579 |
| Fresenius USA Marketing, Inc. | 10 | $168 |
| Calliditas Therapeutics US Inc. | 6 | $148 |
| Sanofi-aventis U.S. LLC | 8 | $130 |
| Corcept Therapeutics | 7 | $128 |
| Novo Nordisk | 6 | $101 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $78 |
| Vifor Pharma, Inc. | 5 | $74 |
| Exact Sciences | 3 | $53 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Indivior Inc. | 3 | $51 |
| Dynavax Technologies Corporation | 2 | $46 |
| Novartis | 3 | $44 |
| Axsome Therapeutics, Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $34 |
| Eisai Inc. | 1 | $31 |
| Johnson & Johnson | 2 | $30 |
| Pfizer | 1 | $29 |
| Nestle Healthcare Nutrition Inc. | 2 | $29 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Ultragenyx Pharmaceutical Inc. | 1 | $25 |
| Radius Health, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $22 |
| Abbott | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $16 |
| Mylan Specialty L.p. | 1 | $15 |
| Lantheus Medical Imaging, Inc. | 1 | $15 |
| Merck | 1 | $14 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$53,594 in reported general payments places this provider in the 95th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KerendiaFinerenone | 196 | $145,392 |
| JardianceEmpagliflozin | 182 | $144,444 |
| FarxigaDapagliflozin Propanediol | 169 | $102,199 |
| VelphoroSucroferric Oxyhydroxide | 14 | $33,242 |
| Eplerenone | 605 | $25,540 |
| EliquisApixaban | 31 | $24,093 |
| VeltassaPatiromer Calcium Sorbitex | 28 | $20,753 |
| JanuviaSitagliptin Phosphate | 19 | $12,869 |
| LokelmaSodium Zirconium Cyclosilicate | 21 | $8,738 |
| Calcitriol | 391 | $3,850 |
| Sevelamer Carbonate | 53 | $3,260 |
| Bumetanide | 51 | $2,109 |
| Torsemide | 131 | $1,818 |
| Carvedilol | 248 | $1,591 |
| Duloxetine Hcl | 96 | $1,508 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BayerKerendia | $18,855 | $145,392196 claims |
| Boehringer IngelheimJardiance | $12,809 | $144,444182 claims |
| AstraZenecaFarxiga, Lokelma | $579 | $110,937190 claims |
| Fresenius USA Marketing, Inc.Velphoro | $168 | $33,24214 claims |
| PfizerEliquis | $29 | $24,09331 claims |
| MerckJanuvia | $14 | $12,86919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 nephrology providers in Georgia.
Other nephrology in Toccoa
- Sagar PanseMacon$542K
- Sheldon ShoreAtlanta$474K
- James TumlinLawrenceville$434K
- Salvatore ChillemiMarietta$287K
- Christina KleinAtlanta$137K
- Mary MuonekeAtlanta$119K
- Don WilliamsonAugusta$104K
- Frederic Rahbari OskouiAtlanta$88K
- Rajendran AlappanColumbus$87K
- William PaxtonLawrenceville$73K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.